白细胞介素-32在子宫内膜异位症发病机制中的作用:体外、人体和转基因小鼠数据
本研究比较了子宫内膜异位症患者与对照者腹腔液中IL-32水平,并通过体外实验和IL-32转基因小鼠模型探讨IL-32在子宫内膜异位症发病中的作用。结果显示晚期子宫内膜异位症患者腹腔液IL-32浓度显著高于对照,IL-32α和γ可增加子宫内膜细胞活力、增殖和侵袭性,转基因小鼠异位病灶更大。提示IL-32可能通过促进子宫内膜细胞增殖和侵袭参与子宫内膜异位症发病。
要点
- 晚期子宫内膜异位症患者腹腔液IL-32浓度显著高于对照。
- IL-32α和γ处理可显著增加Ishikawa细胞和子宫内膜基质细胞的活力、PCNA表达和侵袭性。
- IL-32转基因小鼠异位子宫内膜病灶显著大于野生型,Ki-67抗原和PCNA表达更高。
核心结论
- IL-32可能通过增加子宫内膜细胞的活力、增殖和侵袭参与子宫内膜异位症的发病。
研究设计与样本
- 本研究比较了子宫内膜异位症患者与无子宫内膜异位症女性腹腔液中IL-32水平,使用Ishikawa细胞和子宫内膜基质细胞进行体外实验,并在诱导子宫内膜异位症的IL-32转基因小鼠和野生型小鼠中进行实验。
主要发现
- 晚期子宫内膜异位症患者腹腔液IL-32浓度显著高于对照。
- IL-32α和γ体外处理导致Ishikawa细胞和子宫内膜基质细胞的细胞活力、PCNA表达和侵袭性显著增加。
- IL-32转基因小鼠的异位子宫内膜病灶尺寸显著大于野生型小鼠,且Ki-67抗原和PCNA表达更高。
局限性
- 尚不清楚IL-32是导致子宫内膜异位症发生和/或进展的主要调节因子,还是下游促炎细胞因子之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does interleukin-32 (IL-32) play a role in the pathogenesis of endometriosis? SUMMARY ANSWER: IL-32 might be involved in the pathogenesis of endometriosis through increased viability, proliferation and invasion of endometrial cells. WHAT IS KNOWN ALREADY: Endometriosis is characterized as a chronic inflammatory disease and several proinflammatory cytokines are suggested to be involved in its pathogenesis and pathophysiology. IL-32, recognized as a new proinflammatory cytokine and a strong inducer of other proinflammatory cytokines, has been shown to serve as a key modulator in several chronic inflammatory diseases. STUDY DESIGN, SIZE, DURATION: This study included comparison of IL-32 levels in the peritoneal fluids between women with and without endometriosis, in-vitro experiments using Ishikawa cells and endometrial stromal cells (ESCs), and experiments on IL-32 transgenic mice and wild-type mice with induced endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: IL-32 levels in the peritoneal fluids were measured using enzyme-linked immunosorbent assays. Cell viability, expression of proliferating cell nuclear antigen (PCNA), and cellular invasiveness were analyzed following in-vitro treatment of Ishikawa cells and ESCs with recombinant IL-32 alpha (α) and gamma (γ). Ectopic endometriotic lesions were compared between IL-32 transgenic mice and wild-type mice after autologous endometrial transplantation with immunohistochemistry for Ki-67 antigen and PCNA. MAIN RESULTS AND THE ROLE OF CHANCE: The peritoneal fluid concentration of IL-32 was significantly higher in patients with advanced stage endometriosis compared with the controls. In-vitro treatment with IL-32 α and γ caused significant increases in cellular viability, PCNA expression, and invasiveness in Ishikawa cells and ESCs. The IL-32 transgenic mice had a significantly larger size of the ectopic endometrial lesions with higher expression of Ki-67 antigen and PCNA compared with wild-type mice. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether IL-32 is a main regulator, or one of several downstream proinflammatory cytokines, causing establishment and/or progression of endometriosis. WIDER IMPLICATIONS OF THE FINDINGS: Further investigation on IL-32 signaling pathways may contribute to development a more effective treatment of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI16C1682). None of the authors has anything to disclose.
引用
- Lee MY, Kim SH, Oh YS, et al. Role of interleukin-32 in the pathogenesis of endometriosis: in vitro, human and transgenic mouse data. Hum Reprod. 2018. PMID: 29562285. doi:10.1093/humrep/dey055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。